The Prescribing Information for each product can be found under each of their sections.
Adverse events reporting information can be found at the bottom of this page.
Adcetris® (brentuximab vedotin)
Indications:1
Hodgkin lymphoma:
- Adcetris is indicated for adult patients with previously untreated CD30+ Stage III or IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine and dacarbazine (AVD)*
- Adcetris is indicated for adult patients with previously untreated CD30+ Stage IIB with risk factors, Stage III or Stage IV HL in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone (BrECADD) *
- Adcetris is indicated for the treatment of adult patients with CD30+ HL at increased risk of relapse or progression following autologous stem cell transplant (ASCT)
- Adcetris is indicated for the treatment of adult patients with relapsed or refractory CD30+ HL:
- following ASCT, or
- following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option
Systemic anaplastic large cell lymphoma:
- Adcetris in combination with cyclophosphamide, doxorubicin and prednisone (CHP) is indicated for adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL)
- Adcetris is indicated for the treatment of adult patients with relapsed or refractory sALCL
Cutaneous T-cell lymphoma:
- Adcetris is indicated for the treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy
1. Takeda Products Ireland Ltd. ADCETRIS Summary of Product Characteristics.
POM. For full indication, dosing, contraindications, and safety information please refer to the prescribing information.
* This indication is currently not funded by HSE for use in Ireland.
Alunbrig® (brigatinib)
Indications:1
- Alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.
- Alunbrig is indicated as monotherapy for the treatment of adult patients with ALK-positive advanced NSCLC previously treated with crizotinib.
1. Takeda Products Ireland Ltd. ALUNBRIG Summary of Product Characteristics.
POM. For full indication, dosing, contraindications, and safety information please refer to the prescribing information.
Fruzaqla®▼ (fruquintinib)
Indication:1
Fruzaqla as monotherapy is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan‑based chemotherapies, anti‑VEGF agents, and anti‑EGFR agents, and who have progressed on or are intolerant to treatment with either trifluridine‑tipiracil or regorafenib.
1. Takeda Products Ireland Ltd. FRUZAQLA Summary of Product Characteristics.
▼ This medicinal product is subject to additional monitoring. Adverse Events should be reported to the Pharmacovigilance Unit at the Health Products Regulatory Authority. Reporting forms and information can be found at: www.hpra.ie. Adverse events should also be reported to Takeda at: AE.GBR-IRL@takeda.com.
POM. For full indication, dosing, contraindications, and safety information please refer to the prescribing information.
Ninlaro® (ixazomib)
Indication:1
Ninlaro in combination with lenalidomide and dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
1. Takeda Products Ireland Ltd. NINLARO Summary of Product Characteristics.
POM. For full indication, dosing, contraindications, and safety information please refer to the prescribing information.
